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and distant metastasis-free rates were 86%, 67%, and 38% at 
1 year and 86%, 38%, and 16% at 3 years, respectively. 
Thirteen patients died; the cause of death was tumor 
progression in 10 patients, infectious pneumonia in two, and 
old age in one. The overall and cause-specific survival rates 
were both 73% at 1 year and 23% and 44% at 3 years, 
respectively. The median survival time was 16 months. 
Although all 17 patients developed grade 1–2 radiation 
dermatitis, there were no therapy-related toxicities of grade 
≥3. 
 
Conclusion: Total scalp irradiation with X-rays and electrons 
is safe and effective for local tumor control of angiosarcoma 
of the scalp, but a prophylactic dose of ≤50 Gy in 
conventional fractions may be insufficient to eradicate 
microscopic disease. For gross tumors, a total dose of 70 Gy, 
and >70 Gy for tumors with deep invasion, is recommended. 
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Purpose or Objective: Uveal melanoma (UM) is a life 
threatening intraocular malignant tumor in adults. Gamma 
Knife Stereotactic Radiosurgery (GKSRS) is a well assessed 
strategy for conservative treatment of UM providing 
satisfactory results in terms of survival, local control and eye 
preservation. Despite severe side effects following GKSRS 
have been reported, literature studies designed to 
investigate dose effect relationship of critical structures are 
rather poor. The aim of this work is to develop predictive 
models for radio induced effects in UM patients (pts) treated 
with GKSRS. 
 
Material and Methods: In our institute 149 pts were treated 
with exclusive GKSRS for UM between 1994 and 2014. 
Prospectively collected clinical data are available. For 
66/149 pts, 3D dosimetry data of involved critical structures 
could be recovered: optic nerve (ON), eyeball and posterior 
part of bulb. For this cohort of pts the median follow up of 
2years (6 months-6 years) is available. Cox’s analyses were 
used to identify selected clinical and dosimetric variables as 
independent risk factor of main side effects: cataract, 
radiation vasculopathy (RV), radiation papillopathy (RP) and 
neovascular glaucoma (NVG), visual acuity (VA) reduction > 
20% of basal value (VA20%) and complete loss of basal VA 
(VA100%). ROC curve analysis allowed predicting cut off value 
of significant variables. 
 
Results: The 2 years incidences from our data were: cataract 
39%, RV 10%, RP 12%, NVG 14%, VA20% 59% and VA100% 27%. 
Age and sex did not result significant. Concerning cataract 
the volume of whole bulb receiving more than 30Gy 
(p=0.0004) and tumor thickness (p=0.002) resulted highly 
predictive; best cut off were respectively 82.2mm3 and 
6.6mm. A clear relationship with maximum dose (Dmax) to 
ON was found for RP (p=0.009 cut off: 14.9Gy) and RV 
(p=0.0009 cut off: 23.8Gy). For RV, also tumor in the anterior 
to equator position was predictive (p=0.008). The volume of 
the posterior bulb receiving more than 20Gy (p=0.0003, cut 
off: 413.7mm3) and tumor thickness (p=0.0009 cut off: 
8.7mm) were predictive for NVG. Multivariate analyses 
resulted in two variables predictive model both for VA20% 
(AUC=0.79) and for VA100% (AUC=0.83), including the tumor 
longest basal diameter and Dmax to the ON. The best cut off 
values for the tumor longest basal diameter were 11.6mm for 
VA20% (p=0.02) and 8.98mm for VA100% (p=0.007); the best 
cut off values for Dmax to the ON were 7.8Gy (p=0.045) for 
VA20% and 13.2Gy (p=0.002) for VA100%. A summary of the 





Conclusion: We found clinical and dosimetric variables to 
clearly predict the risk of the main side effects after GKSRS 
for UM. These results may provide new dose constraints to 
critical structures, that once implemented during treatment 
planning, could reduce radiation toxicities. Further 
investigation to create bulb dose surface maps highlighting 
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Purpose or Objective: Choroidal melanoma is the most 
frequent malignant tumour of the eye. Eye-conserving 
treatment with Ruthenium-106 brachytherapy (RuBT) is a 
standard treatment for patients with small to intermediate 
size melanomas. The present study was done to evaluate 
